Trial Outcomes & Findings for A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects (NCT NCT01015976)

NCT ID: NCT01015976

Last Updated: 2014-03-31

Results Overview

AUC of surgery group compared to the AUC of control group

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

10 participants

Primary outcome timeframe

0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3.5, 4.5, 6.5, 8.5, 10.5 hours

Results posted on

2014-03-31

Participant Flow

Participant milestones

Participant milestones
Measure
Experimental
Post surgery group Sertraline : Single dose of 100mg sertraline
Control Group
active drug No surgery matched subjects
Overall Study
STARTED
5
5
Overall Study
COMPLETED
5
5
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Active Drug
n=10 Participants
Single arm study, all receive active drug Sertraline : Single dose of 100mg sertraline
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
10 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Age, Continuous
46.6 years
STANDARD_DEVIATION 10.6 • n=5 Participants
Sex: Female, Male
Female
10 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
Region of Enrollment
United States
10 participants
n=5 Participants

PRIMARY outcome

Timeframe: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3.5, 4.5, 6.5, 8.5, 10.5 hours

Population: Per protocol

AUC of surgery group compared to the AUC of control group

Outcome measures

Outcome measures
Measure
Control
n=10 Participants
Single arm study, all receive active drug Sertraline : Single dose of 100mg sertraline
AUC Post Surgery (n =5) Compared to AUC Control (n=5)
Post surgery
124.4 ng-hr/mL
Standard Deviation 55.5
AUC Post Surgery (n =5) Compared to AUC Control (n=5)
Control
314.8 ng-hr/mL
Standard Deviation 129.6

Adverse Events

Active Drug

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

James L. Roerig PharmD, BCPP

University of North Dakota - Neuropsychiatric Research Institute

Phone: 701 365 4919

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place